Rx Product News (February 2018)

Pharmacy Times, February 2018 Infectious Disease, Volume 84, Issue 2

Rx product news featured in the February 2018 issue of Pharmacy Times.

SEMAGLUTIDEMANUFACTURED BY: Novo Nordisk

INDICATION: The FDA has approved semaglutide (Ozempic) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

DOSAGE FORM: Injection: 0.5 mg or 1 mg

FOR MORE INFORMATION: novonordisk-us.com

TALTZMANUFACTURED BY: Eli Lilly

INDICATION: The FDA has approved ixekizumab (Taltz) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis. Ixekizumab was previously approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

DOSAGE FORM: Subcutaneous injection, 80 mg/mL

FOR MORE INFORMATION: lilly.com

REPATHAMANUFACTURED BY: Amgen

INDICATION: The FDA has OK’d Amgen’s evolocumab (Repatha) as the first proprotein convertase subtilisin/ kexin type 9 inhibitor to prevent heart attacks, strokes, and coronary revascularizations in adults with established heart disease.

DOSAGE FORM: Subcutaneous injection, 420 mg, once a month

FOR MORE INFORMATION: amgen.com

LONHALAMAGNAIR MANUFACTURED BY: PARI Pharma GmbH, Sunovion

INDICATION: The FDA has approved PARI Pharma’s eFlow closed system nebulizer Magnair together with Sunovion’s glycopyrrolate (Lonhala) inhalation solution for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including bronchitis and/ or emphysema. Lonhala Magnair is the first nebulized long-acting muscarinic antagonist treatment option for patients with COPD.

DOSAGE FORM: Inhalation solution, 25 mcg

FOR MORE INFORMATION: paripharma.com, sunovion.com